PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2D324F288S4565947815!imipenem and cilastatin SODIUM f INJ — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2D021DA002. PoP ended Sep 27, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Dms Pharmaceutical Group Inc

Recipient

Sep 27, 2024

PoP end

$126K

Obligated

$126K

Potential

325411

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal

Contract numberSPE2D324F288S

Also listed asSPE2D021DA002-SPE2D324F288S

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentDms Pharmaceutical Group Inc

CAGE1UNB0

UEIPX72BSBQTKJ3

NAICS325411

No full NAICS 325411 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2D021DA002

Place of performancePARK RIDGE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 26, 2024

PoP end (current)Sep 27, 2024

Obligated$126K

Current value$126K

Potential value$126K

4565947815!IMIPENEM AND CILASTATIN SODIUM F/INJ 500 is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $126K ($126K obligated). Current period of performance ends Sep 27, 2024. Place of performance: PARK RIDGE IL.

4565947815!IMIPENEM AND CILASTATIN SODIUM F/INJ 500

Recompete timing

Public

● Past PoP end (693 days ago)

Current PoP ended Sep 27, 2024 (693 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies

Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0120

8511978882!OTHER MEDICAL

$248K

Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2D324F288S?

SPE2D324F288S (4565947815!imipenem and cilastatin SODIUM f INJ) is a Dla Troop Support award with a potential value of $126K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2D324F288S?

Dla Troop Support awarded SPE2D324F288S to Dms Pharmaceutical Group Inc (potential $126K).

Who is the incumbent on SPE2D324F288S?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Sep 27, 2024.

When does Dms Pharmaceutical Group Inc’s SPE2D324F288S come up for recompete?

SCOUT tracks a period-of-performance end of Sep 27, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Sep 26, 2024